{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:33:07Z","timestamp":1793665987020,"version":"4.5.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015993","name":"Kowa Company, Ltd.","doi-asserted-by":"crossref","award":["Award No.:N\/A"],"award-info":[{"award-number":["Award No.:N\/A"]}],"id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ripasudil is approved in Japan for glaucoma or ocular hypertension (OH) when other treatments are ineffective or cannot be administered. Its long-term safety and efficacy are being examined in a post-marketing surveillance study; 12-month data are described here.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective, open-label, observational study enrolled patients with glaucoma or OH who started ripasudil during routine care. The key safety outcome was the incidence of adverse drug reactions (ADRs), focusing on allergy and\/or inflammation-related ADRs such as blepharitis (including allergic) or conjunctivitis (including allergic). The primary efficacy endpoint was least squares mean (LSM)\u2009\u00b1\u2009standard error (SE) change in intraocular pressure (IOP) from baseline to 12\u2009months in all patients and in diagnostic groups. Secondary endpoints were change in IOP in groups stratified by treatment initiation pattern, number of concomitant drugs, and baseline IOP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 3359 patients (48% male, mean age\u2009\u00b1\u2009standard deviation [SD] 69.1\u2009\u00b1\u200912.7\u2009years) were evaluated for safety and 3323 for efficacy. Diagnoses were primary open-angle glaucoma (43.9%), normal-tension glaucoma (36.6%), secondary glaucoma (8.7%), OH (4.2%), and primary closed-angle glaucoma (2.4%). Mean\u2009\u00b1\u2009SD observation period was 300.1\u2009\u00b1\u2009122.4\u2009days; 1010 patients (30.1%) discontinued ripasudil by 12\u2009months. ADRs occurred in 626 patients (18.6%); the most common were conjunctival hyperemia and blepharitis. Allergy and\/or inflammation-related ADRs occurred in 388 patients (11.6%), most commonly blepharitis (5.6%) and conjunctivitis (4.2%). IOP decreased significantly from a mean\u2009\u00b1\u2009SD 18.1\u2009\u00b1\u20096.1\u2009mmHg at baseline; the LSM\u2009\u00b1\u2009SE IOP change throughout 12\u2009months of ripasudil treatment was \u2212\u20092.6\u2009\u00b1\u20090.1\u2009mmHg (\u2212\u200914.0\u2009\u00b1\u20090.4%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). A significant decrease in IOP at 12\u2009months was seen in all categories of baseline IOP (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and all types of glaucoma (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), except neovascular glaucoma. Ripasudil was associated with a significant reduction in IOP at 12\u2009months whether initiated as monotherapy or in combination with \u22644 concomitant glaucoma therapies (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Ripasudil was safe and effective in patients with glaucoma or OH during routine care. No new safety signals were identified, and significant reductions in IOP were maintained over 12\u2009months.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-020-01490-1","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T16:06:44Z","timestamp":1594310804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study"],"prefix":"10.1186","volume":"20","author":[{"given":"Hidenobu","family":"Tanihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Kakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Gunji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"issue":"18","key":"1490_CR1","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901\u201311.","journal-title":"JAMA"},{"issue":"11","key":"1490_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081\u201390.","journal-title":"Ophthalmology"},{"issue":"10","key":"1490_CR3","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.ophtha.2005.05.012","volume":"112","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Iwase A, Araie M, Suzuki Y, Abe H, Shirato S, Kuwayama Y, Mishima HK, Shimizu H, Tomita G, et al. The Tajimi study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005;112(10):1661\u20139.","journal-title":"Ophthalmology"},{"issue":"1","key":"1490_CR4","first-page":"5","volume":"122","author":"Japan Glaucoma Society","year":"2018","unstructured":"Japan Glaucoma Society. The Japan guidelines for Glaucoma (fourth edition). Nippon Ganka Gakkai Zasshi. 2018;122(1):5\u201353.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"1","key":"1490_CR5","doi-asserted-by":"publisher","first-page":"P41","DOI":"10.1016\/j.ophtha.2015.10.053","volume":"123","author":"BE Prum Jr","year":"2016","unstructured":"Prum BE Jr, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, Herndon LW Jr, Lim MC, Williams RD. Primary open-angle Glaucoma preferred practice pattern\u00ae guidelines. Ophthalmology. 2016;123(1):P41\u2013111.","journal-title":"Ophthalmology"},{"key":"1490_CR6","unstructured":"National Institute for Health and Care Excellence. Glaucoma: diagnosis and management. NICE Guideline; 2017. Available at: https:\/\/www.nice.org.uk\/guidance\/ng81. Accessed 13 June 2019."},{"issue":"2","key":"1490_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10384-018-0566-9","volume":"62","author":"M Honjo","year":"2018","unstructured":"Honjo M, Tanihara H. Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma. Jpn J Ophthalmol. 2018;62(2):109\u201326.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"1490_CR8","first-page":"137","volume":"42","author":"M Honjo","year":"2001","unstructured":"Honjo M, Tanihara H, Inatani M, Kido N, Sawamura T, Yue BY, Narumiya S, Honda Y. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42(1):137\u201344.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1490_CR9","first-page":"1029","volume":"42","author":"PV Rao","year":"2001","unstructured":"Rao PV, Deng P-F, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the rho kinase\u2013specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42(5):1029\u201337.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"1490_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archophthalmol.2007.76","volume":"126","author":"H Tanihara","year":"2008","unstructured":"Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126(3):309\u201315.","journal-title":"Arch Ophthalmol"},{"issue":"18","key":"1490_CR11","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","volume":"74","author":"KP Garnock-Jones","year":"2014","unstructured":"Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74(18):2211\u20135.","journal-title":"Drugs"},{"issue":"15","key":"1490_CR12","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1080\/14656566.2017.1378344","volume":"18","author":"T Inoue","year":"2017","unstructured":"Inoue T, Tanihara H. Ripasudil hydrochloride hydrate: targeting rho kinase in the treatment of glaucoma. Expert Opin Pharmacother. 2017;18(15):1669\u201373.","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"1490_CR13","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","volume":"131","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 1 clinical trials of a selective rho kinase inhibitor, K-115. JAMA Ophthalmol. 2013;131(10):1288\u201395.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"1490_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","volume":"156","author":"H Tanihara","year":"2013","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2013;156(4):731\u20136 e732.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1490_CR15","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.12829","volume":"94","author":"H Tanihara","year":"2016","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Fukushima A, Suganami H, Araie M. K-115 clinical study group, Uchino M: one-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94(1):e26\u201334.","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"1490_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","volume":"133","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, Araie M. Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133(7):755\u201361.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"1490_CR17","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1111\/aos.12599","volume":"93","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, Araie M. K-115 clinical study group: intra-ocular pressure-lowering effects of a rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93(4):e254\u201360.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"1490_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12325-018-0863-1","volume":"36","author":"H Tanihara","year":"2019","unstructured":"Tanihara H, Kakuda T, Sano T, Kanno T, Imada R, Shingaki W, Gunji R. Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 3-month interim analysis of ROCK-J, a post-marketing surveillance study. Adv Ther. 2019;36(2):333\u201343.","journal-title":"Adv Ther"},{"issue":"1","key":"1490_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10384-013-0284-2","volume":"58","author":"K Kashiwagi","year":"2014","unstructured":"Kashiwagi K, Furuya T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol. 2014;58(1):68\u201374.","journal-title":"Jpn J Ophthalmol"},{"issue":"7","key":"1490_CR20","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, Lee PP. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122(7):1308\u201316.","journal-title":"Ophthalmology"},{"issue":"9","key":"1490_CR21","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1751-7176.2008.00006.x","volume":"10","author":"SG Chrysant","year":"2008","unstructured":"Chrysant SG. Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema. J Clin Hypertens (Greenwich). 2008;10(9):716\u201322.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"1490_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1046\/j.0306-5251.2001.01547.x","volume":"53","author":"N Jarernsiripornkul","year":"2002","unstructured":"Jarernsiripornkul N, Krska J, Capps PA, Richards RM, Lee A. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol. 2002;53(3):318\u201325.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1490_CR23","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1038\/s41598-019-40255-9","volume":"9","author":"E Sakamoto","year":"2019","unstructured":"Sakamoto E, Ishida W, Sumi T, Kishimoto T, Tada K, Fukuda K, Yoneda T, Kuroiwa H, Terao E, Fujisawa Y, et al. Evaluation of offset of conjunctival hyperemia induced by a Rho-kinase inhibitor; 0.4% ripasudil ophthalmic solution clinical trial. Sci Rep. 2019;9(1):3755.","journal-title":"Sci Rep"},{"key":"1490_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC. Rocket, groups R-S: two phase 3 clinical trials comparing the safety and efficacy of Netarsudil to Timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116\u201327.","journal-title":"Am J Ophthalmol"},{"key":"1490_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","volume":"200","author":"MY Kahook","year":"2019","unstructured":"Kahook MY, Serle JB, Mah FS, Kim T, Raizman MB, Heah T, Ramirez-Davis N, Kopczynski CC, Usner DW, Novack GD, et al. Long-term safety and ocular hypotensive efficacy evaluation of Netarsudil ophthalmic solution: rho kinase elevated IOP treatment trial (ROCKET-2). Am J Ophthalmol. 2019;200:130\u20137.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1490_CR26","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1167\/iovs.15-18586","volume":"57","author":"N Okumura","year":"2016","unstructured":"Okumura N, Okazaki Y, Inoue R, Kakutani K, Nakano S, Kinoshita S, Koizumi N. Effect of the rho-associated kinase inhibitor eye drop (Ripasudil) on corneal endothelial wound healing. Invest Ophthalmol Vis Sci. 2016;57(3):1284\u201392.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1490_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000431196","volume":"55","author":"SJ Havens","year":"2016","unstructured":"Havens SJ, Gulati V. Neovascular glaucoma. Dev Ophthalmol. 2016;55:196\u2013204.","journal-title":"Dev Ophthalmol"}],"updated-by":[{"DOI":"10.1186\/s12886-020-01595-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000}}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01490-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-020-01490-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01490-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T23:17:14Z","timestamp":1625786234000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01490-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01490-1","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12886-020-01595-7","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted as a multi-center, open-label, prospective, non-interventional study, conducted in accordance with the Ministerial Ordinance on Good Post-Marketing Study Practice (Ministry of Health, Labour and Welfare Ordinance No. 171, December 20, 2004). The study protocol was review and approved by the Japanese regulatory authority before initiation. This study did not undergo review by the ethics committee of the participating medical institutions or the informed consent procedure, unless such procedures were required by individual participating medical institution.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HT has received research funding from Kowa, Santen Pharmaceutical and Senju Pharmaceutical, consulting fees from Kowa, Aerie Pharmaceuticals, Inc., Santen Pharmaceutical and Wakamoto Pharmaceutical, and honoraria for lectures from Kowa, Senju Pharmaceutical, Santen Pharmaceutical, Otsuka Pharma Co. Ltd., Pfizer, Rohto Pharmaceutical, Wakamoto Pharmaceutical, HOYA Corporation, Mitsubishi Tanabe Pharma, Glaukos Japan and Novartis Pharma. T Kakuda, TS, T Kanno and RG are employees of Kowa Co., Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}